See more : Synergia Energy Ltd (OEX.L) Income Statement Analysis – Financial Results
Complete financial analysis of Evelo Biosciences, Inc. (EVLO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evelo Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- LAUNXP Biomedical Co., Ltd (6876.TWO) Income Statement Analysis – Financial Results
- Ningbo Jianan Electronics Co.,Ltd (300880.SZ) Income Statement Analysis – Financial Results
- Asahi Diamond Industrial Co., Ltd. (6140.T) Income Statement Analysis – Financial Results
- Guangzhou Sanfu New Materials Technology Co.,Ltd (688359.SS) Income Statement Analysis – Financial Results
- Rieter Holding AG (RIEN.SW) Income Statement Analysis – Financial Results
Evelo Biosciences, Inc. (EVLO)
About Evelo Biosciences, Inc.
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 78.55M | 83.64M | 69.62M | 63.13M | 39.89M | 19.96M | 9.13M |
| General & Administrative | 29.91M | 31.75M | 22.27M | 23.23M | 18.22M | 7.57M | 3.89M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.91M | 31.75M | 22.27M | 23.23M | 18.22M | 7.57M | 3.89M |
| Other Expenses | 0.00 | 486.00K | -1.37M | 1.08M | 1.16M | -301.00K | -20.00K |
| Operating Expenses | 108.47M | 115.40M | 91.89M | 86.36M | 58.10M | 27.53M | 13.03M |
| Cost & Expenses | 108.47M | 115.40M | 91.89M | 86.36M | 58.10M | 27.53M | 13.03M |
| Interest Income | 4.67K | 3.61K | 0.00 | 1.05K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.67M | 3.61M | 2.11M | 1.05M | 1.56M | 0.00 | 0.00 |
| Depreciation & Amortization | 2.06M | 2.22M | 2.03M | 1.76K | 1.94K | 834.00 | 495.00 |
| EBITDA | -106.35M | -115.40M | -91.89M | -86.36M | -58.10M | -26.70M | -12.53M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -108.47M | -115.40M | -91.89M | -86.36M | -58.10M | -27.53M | -13.03M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.13M | -6.35M | -1.37M | 885.00K | 1.16M | -516.00K | -307.00K |
| Income Before Tax | -113.60M | -121.75M | -93.26M | -85.47M | -56.95M | -28.05M | -13.33M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 930.00K | 428.00K | 409.00K | 190.00K | -3.09M | 215.00K | 287.00K |
| Net Income | -114.53M | -122.18M | -93.67M | -85.66M | -53.85M | -28.05M | -13.33M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -26.28 | -46.18 | -47.45 | -53.49 | -49.25 | -149.98 | -94.55 |
| EPS Diluted | -26.28 | -46.18 | -47.45 | -53.49 | -49.25 | -149.55 | -94.06 |
| Weighted Avg Shares Out | 4.36M | 2.65M | 1.97M | 1.60M | 1.09M | 187.00K | 141.00K |
| Weighted Avg Shares Out (Dil) | 4.36M | 2.65M | 1.97M | 1.60M | 1.09M | 187.54K | 141.74K |
Evelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q3 2021 Results - Earnings Call Transcript
Evelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q3 2021 Results - Earnings Call Transcript
Wall Street Analysts Believe Evelo Biosciences, Inc. (EVLO) Could Rally 164%: Here's is How to Trade
The consensus price target hints at a 164.5% upside potential for Evelo Biosciences, Inc. (EVLO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness...
Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
–Data suggest SINTAX™ medicine may overcome blood-brain barrier limitations to anti-inflammatory drug delivery– –EDP1867 reduced disease severity and incidence of relapse in murine model of multiple sclerosis– –Data support development of EDP1867 for the treatment of neuroinflammatory diseases–
Evelo (EVLO) Posts Positive Data from Phase II Psoriasis Study
Evelo Biosciences (EVLO) reports encouraging data from a phase II study evaluating EDP1815 for the treatment of mild and moderate psoriasis. Shares up in pre-market trading.
Evelo Biosciences Psoriasis Candidate Shows Benefit In Mid-Stage Study
Evelo Biosciences Inc (NASDAQ: EVLO) has announced data from its Phase 2 study of EDP1815 for mild and moderate psoriasis. A statistically significant reduction in the Psoriasis Area and Severity Index (PASI) score from baseline at week 16 was observed in the study.
Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the Small Intestinal Axis, SINTAX™, to Treat Systemic Inflammatory Disease
–Clinically and statistically significant improvement in PASI-50 score achieved––EDP1815 safety and tolerability data comparable to placebo in study––EDP1815 advancing towards registration studies in psoriasis––Management to host conference call at 8:00 a.m. ET–
Implied Volatility Surging for Evelo Biosciences (EVLO) Stock Options
Investors need to pay close attention to Evelo Biosciences (EVLO) stock based on the movements in the options market lately.
Evelo Biosciences Appoints Iain McInnes, M.B.Ch.B, Ph.D, to Board of Directors
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointment of Iain McInnes, M.B.Ch.B, Ph.D., to its Board of Directors.
Evelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q2 2021 Results - Earnings Call Transcript
Evelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q2 2021 Results - Earnings Call Transcript
Evelo Biosciences Reports Second Quarter 2021 Financial Results and Business Highlights
–EDP1815 Phase 2b data in psoriasis expected in 3Q 2021––Finalized design of Phase 2 clinical trial of EDP1815 in atopic dermatitis; start of trial anticipated in 3Q 2021––Strengthened leadership team with appointment of Mark Plinio as Chief Commercial Officer––Multiple clinical...
Source: https://incomestatements.info
Category: Stock Reports